Log in

NYSE:HQLTekla Life Sciences Investors Stock Price, Forecast & News

$17.90
-0.04 (-0.22 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.80
Now: $17.90
$17.95
50-Day Range
$17.60
MA: $18.25
$19.06
52-Week Range
$11.45
Now: $17.90
$19.28
Volume61,999 shs
Average Volume110,695 shs
Market Capitalization$407.33 million
P/E RatioN/A
Dividend Yield7.97%
Beta1.21
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Investment offices, not elsewhere classified
Sub-IndustryN/A
SectorFinance
CUSIPN/A
Phone617-772-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$407.33 million
Next Earnings DateN/A
OptionableNot Optionable
$17.90
-0.04 (-0.22 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HQL News and Ratings via Email

Sign-up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions

How has Tekla Life Sciences Investors' stock price been impacted by Coronavirus (COVID-19)?

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HQL stock has increased by 20.5% and is now trading at $17.90.
View which stocks have been most impacted by COVID-19
.

How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?

Tekla Life Sciences Investors announced a quarterly dividend on Tuesday, May 19th. Stockholders of record on Friday, May 29th will be paid a dividend of $0.34 per share on Tuesday, June 30th. This represents a $1.36 dividend on an annualized basis and a yield of 7.60%. The ex-dividend date of this dividend is Thursday, May 28th.
View Tekla Life Sciences Investors' dividend history
.

Has Tekla Life Sciences Investors been receiving favorable news coverage?

Press coverage about HQL stock has been trending negative on Saturday, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tekla Life Sciences Investors earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Tekla Life Sciences Investors
.

Are investors shorting Tekla Life Sciences Investors?

Tekla Life Sciences Investors saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 11,300 shares, a decrease of 65.7% from the June 15th total of 32,900 shares. Based on an average daily volume of 101,700 shares, the days-to-cover ratio is presently 0.1 days.
View Tekla Life Sciences Investors' Short Interest
.

Who are some of Tekla Life Sciences Investors' key competitors?

What other stocks do shareholders of Tekla Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include QUALCOMM (QCOM), NVIDIA (NVDA), Energy Transfer LP Unit (ET), AT&T (T), Enbridge (ENB), IBM (IBM), Main Street Capital (MAIN), Pfizer (PFE), Weyerhaeuser (WY) and BP (BP).

Who are Tekla Life Sciences Investors' key executives?

Tekla Life Sciences Investors' management team includes the following people:
  • Dr. Daniel R. Omstead M.S, Ph.D., Principal Exec. Officer, Pres and Trustee (Age 66)
  • Ms. Laura F. Woodward, Principal Financial Officer, Chief Compliance Officer, Sec. and Treasurer (Age 51)
  • Ms. Betty T. Chang, Assistant Treasurer (Age 47)

What is Tekla Life Sciences Investors' stock symbol?

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

Who are Tekla Life Sciences Investors' major shareholders?

Tekla Life Sciences Investors' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Matisse Capital (1.42%), Flagship Harbor Advisors LLC (1.25%), Advisors Asset Management Inc. (1.17%), Advisor Group Holdings Inc. (0.55%), RMB Capital Management LLC (0.42%) and UBS Group AG (0.41%).
View institutional ownership trends for Tekla Life Sciences Investors
.

Which major investors are selling Tekla Life Sciences Investors stock?

HQL stock was sold by a variety of institutional investors in the last quarter, including RMB Capital Management LLC, Bank of America Corp DE, Mid Atlantic Financial Management Inc. ADV, 180 Wealth Advisors LLC, Janney Montgomery Scott LLC, Raymond James Financial Services Advisors Inc., CWM LLC, and Stifel Financial Corp.
View insider buying and selling activity for Tekla Life Sciences Investors
.

Which major investors are buying Tekla Life Sciences Investors stock?

HQL stock was acquired by a variety of institutional investors in the last quarter, including Matisse Capital, UBS Group AG, Advisors Asset Management Inc., AE Wealth Management LLC, Sawtooth Solutions LLC, Vanguard Capital Wealth Advisors, Live Oak Private Wealth LLC, and Advisor Group Holdings Inc..
View insider buying and selling activity for Tekla Life Sciences Investors
.

How do I buy shares of Tekla Life Sciences Investors?

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tekla Life Sciences Investors' stock price today?

One share of HQL stock can currently be purchased for approximately $17.90.

How big of a company is Tekla Life Sciences Investors?

Tekla Life Sciences Investors has a market capitalization of $407.33 million.

What is Tekla Life Sciences Investors' official website?

The official website for Tekla Life Sciences Investors is www.teklacap.com.

How can I contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.